Dermatology (drugs I-Z)

(Orencia®, Otezla®, Siliq™, Simponi®, Stelara®, Taltz®)

DIPLOMAT®

--Select One--
Phone
Fax
Insert Sales Contact Name (if known)

Patient Information

Patient name: _____ DOB: _____
Sex: ☐ Female ☐ Male SSN: _____
Language: _____ Wt: _____ ☐kg ☐lbs Ht: _____☐cm ☐in
Address: _____
Apt/Suite: _____ City: _____ State: _____ Zip: _____
Phone: _____ Alternate: _____
Caregiver name: _____ Relation: _____
Local pharmacy: _____ Phone: _____
Insurance plan: _____ Plan ID: _____
Please fax a copy of front and back of the insurance card(s).

Prescriber + Shipping Information

Prescriber name: _____
NPI: _____
Address: _____
Apt/Suite: _____ City: _____ State: _____ Zip: _____
Contact: _____
Phone: _____ Alternate: _____
Fax: _____
Email: _____
If shipping to prescriber: ☐ First Fill ☐ Always ☐Never

Clinical Information (Please fax all pertinent clinical and lab information)

Diagnosis: ☐ L40.0 (Psoriasis vulgaris/Plaque Psoriasis/Nummular Psoriasis) ☐ L40.8 (Other psoriasis)
☐ L40.9 (Psoriasis, unspecified) ☐ L40.5____ (Psoriatic arthritis) ☐ L73.2 (Hidradenitis Suppurativa) ☐ _____
Diagnosis Date: _____ TB test: ☐ Yes ☐ No Neg. Test Date: _____ HBV: ☐ Yes ☐ No If yes, currently treated: ☐ Yes ☐ No
BSA affected (%): _____ Affected areas: ☐ Palms ☐ Soles ☐ Head ☐ Neck ☐ Genitalia ☐ _____

Prior Therapy ☐ Yes ☐ No	Reason for Discontinuation of Therapy	Approximate Start Date	Approximate End Date

Comorbidities: _____
Concomitant Medications: _____
Allergies: ☐ NKDA ☐ Other: _____

Prescription

Prescription		Quantity		Refill
§ Cimzia®, Cosentyx®, Dupixent®, Enbrel®, Humira® are available on the Dermatology Enrollment Form A-H §				
☐ **Orencia® (abatacept)** *Psoriatic Arthritis*	☐ Infuse _____ mg at week 0 and 2	☐ _____ x 250 mg/mL	Vials	0
	☐ Infuse _____ mg at week 4 and every 4 weeks thereafter	☐ _____ x 250 mg/mL	Vials	_____
	< 60 kg = 500 mg, 60 to 100 kg = 750 mg, > 100 kg = 1000 mg			
	☐ Inject 125 mg subcut once weekly	☐ 4 x 125 mg/mL	☐ PFS ☐ ClickJect™ Autoinjector	_____
☐ **Otezla® (apremilast)**	☐ Take as directed per package instructions	☐ 55 tablets	28-day starter pack	0
	☐ Take 30 mg by mouth twice daily ☐ _____	☐ 60 x 30 mg tablets ☐ _____		_____
☐ **Siliq™ (brodalumab)**	☐ Inject 210 mg subcut on weeks 0, 1, and 2 followed by 210 mg subcut every 2 weeks thereafter	☐ 3 x 210 mg/1.5 mL	PFS	0
	☐ Inject 210 mg subcut every 2 weeks	☐ 2 x 210 mg/1.5 mL	PFS	_____
☐ **Simponi® (golimumab)** *Psoriatic Arthritis*	☐ Inject 50 mg subcut once a month	☐ 1 x 50 mg/0.5mL	☐ SmartJect® Autoinjector ☐ PFS	_____
☐ **Stelara® (ustekinumab)**	☐ Inject 45 mg subcut on Day 1 (≤100 kg) ☐ Inject 90 mg subcut on Day 1 (>100 kg)	☐ 1 x 45 mg/0.5mL ☐ 1 x 90 mg/mL	PFS	0
	☐ Inject 45 mg subcut on Day 29 and every 12 weeks thereafter (≤100 kg) ☐ Inject 90 mg subcut on Day 29 and every 12 weeks thereafter (>100 kg)	☐ 1 x 45 mg/0.5mL ☐ 1 x 90 mg/mL	PFS	_____
	Patient eligible for self-administration: ☐ Yes ☐ No			
☐ **Taltz® (Ixekizumab)**	☐ Weeks 0 - 2: Inject 160 mg (2 x 80 mg) subcut at week 0, then inject 80 mg subcut at week 2	☐ 3 x 80 mg/mL	☐ Autoinjectors ☐ PFS	0
	☐ Weeks 4 - 10: Inject 80 mg subcut at week 4 and every **two** weeks thereafter through week 10	☐ 2 x 80 mg/mL	☐ Autoinjectors ☐ PFS	1
	☐ Week 12 onwards: Inject 80 mg subcut at week 12 and every **four** weeks thereafter	☐ 1 x 80 mg/mL	☐ Autoinjectors ☐ PFS	_____

Injection Training Provided by: ☐ Physician's Office ☐ Pharmacy ☐Other: _____

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: _____

Stamp signature not allowed, physician signature required.

Prescriber's Signature: _____ Date: _____

I authorize Diplomat Pharmacy, Inc. and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to Diplomat Pharmacy, Inc.

Reset Form